Novo Nordisk A/S (NVO)
47.08
+0.31
(+0.66%)
USD |
NYSE |
Sep 03, 16:00
47.35
+0.27
(+0.57%)
After-Hours: 20:00
Novo Nordisk Net Income (Annual) : 15.49B for Dec. 31, 2025
Net Income (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 15.49B |
| December 31, 2024 | 14.65B |
| December 31, 2023 | 12.14B |
| December 31, 2022 | 7.844B |
| December 31, 2021 | 7.590B |
| December 31, 2020 | 6.444B |
| December 31, 2019 | 5.839B |
| December 31, 2018 | 6.114B |
| December 31, 2017 | 5.782B |
| December 31, 2016 | 5.635B |
| December 31, 2015 | 5.183B |
| December 31, 2014 | 4.712B |
| December 31, 2013 | 4.483B |
| December 31, 2012 | 3.698B |
| December 31, 2011 | 3.191B |
| December 31, 2010 | 2.559B |
| December 31, 2009 | 2.011B |
| December 31, 2008 | 1.893B |
| December 31, 2007 | 1.566B |
| December 31, 2006 | 1.086B |
| December 31, 2005 | 977.42M |
| December 31, 2004 | 837.09M |
| December 31, 2003 | 738.86M |
| Date | Value |
|---|---|
| December 31, 2002 | 519.65M |
| December 31, 2001 | 463.96M |
| December 31, 2000 | 381.39M |
| December 31, 1999 | 345.04M |
| December 31, 1998 | 358.74M |
| December 31, 1997 | 334.88M |
| December 31, 1996 | 309.78M |
| December 31, 1995 | 279.09M |
| December 31, 1994 | 225.34M |
| December 31, 1993 | 220.01M |
| December 31, 1992 | 211.61M |
| December 31, 1991 | 145.08M |
| December 31, 1990 | 122.93M |
| December 31, 1989 | 102.20M |
| December 31, 1988 | 94.71M |
| December 31, 1987 | 70.62M |
| December 31, 1986 | 64.09M |
| December 31, 1985 | 57.20M |
| December 31, 1984 | 66.23M |
| December 31, 1983 | 74.99M |
| December 31, 1982 | 66.27M |
| December 31, 1981 | 47.85M |
| December 31, 1980 | 31.25M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Annual) Benchmarks
| AstraZeneca PLC | 10.26B |
| Johnson & Johnson | 26.80B |
| Eli Lilly & Co. | 20.64B |
| Merck & Co., Inc. | 18.26B |
| Novartis AG | 14.04B |